Skip to main content
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
    • Investor materials
    • Events
    • SEC filings
    • Stock information
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX 117
      • ARGX 118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
    • Investor materials
    • Events
    • SEC filings
    • Stock information
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us

Breadcrumb

  1. Home
  2. Pipeline
  3. ARGX-116

ARGX-116

STT-5058 (ARGX-116) was designed as a SIMPLE Antibody® inhibitor of ApoC3. STT-5058 is a sweeping antibody with recycling properties that are pH-dependent and enable clearing multiple apoC3-containing lipoproteins. Staten is evaluating the antibody for its potential in dyslipidemia management.

Publications

A list of related publications.

ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX 117
      • ARGX 118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
    • Investor materials
    • Events
    • SEC filings
    • Stock information
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
2021 © Argenx
Disclaimer
Privacy policy
You are now leaving the argenx web site

This link will take you to a site maintained by a third party, which is responsible for its contents.

OK